Boston Scientific Corporation vs Vanguard S&P 500 ETF — how do they compare? Boston Scientific Corporation trades at $43.03 (market cap $66.37B), while Vanguard S&P 500 ETF trades at $694.36. The key difference: Vanguard S&P 500 ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | VOO | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $108.14 | $698.29 |
52-Week Low | $42.63 | $571.45 |
Enterprise Value | $75.94B | — |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
VOO, the Vanguard S&P 500 ETF, trades at $688.55, down 0.76% over the past day. Technical indicators show a bullish moving average trend but neutral oscillators, with support near $686 and resistance at $692. The ETF provides diversified exposure to large-cap U.S. stocks, with a dividend of $1.96 scheduled for June 2026. Recent news highlights ongoing discussions about S&P 500 valuations and potential market catalysts from earnings season.
Outlook remains tied to broad market performance, with analysts projecting further S&P 500 gains amid economic resilience. Risks include market volatility and high valuations. The ETF offers a low-cost, passive investment avenue, but investors should monitor macroeconomic trends and earnings results for directional cues.
Trailing returns across standard periods
Latest headlines on both assets
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →